Developer docs
API playgroundTry for free, no card

Search company profiles

Impact Biomedical

Full company profile

uuid00039fr

Namestring
Impact Biomedical
Legal namestring
Impact BioMedical Inc.
Company typeenum
Public
Founded yearint
2024
Descriptiontext

Impact BioMedical Inc. is a publicly traded biotechnology and consumer wellness company (NYSE American: IBO), headquartered in Houston, Texas, that develops and patents science-based platforms targeting inflammatory disease, oncology, neurology, metabolic disorders, infectious disease, and indoor air quality. The company was spun out of DSS Inc. through an IPO in September 2024 and operates four core technology platforms: Linebacker (small-molecule X-bonded polyphenols designed to down-regulate PIM kinase for solid tumor cancers and inflammatory/neurological disorders), Laetose (a patented low-glycemic sugar composition with myo-inositol that inhibits TNF-alpha, covered by US Patent #11,898,184), Equivir (an FDA GRAS-eligible polyphenol blend with antiviral effects intended for OTC respiratory infection applications), and 3F (a botanical terpene-based formulation with insect repellent and antimicrobial properties). In February 2025 the company expanded into air purification via the acquisition of Celios, contributing its first reported revenue and adding design, system, and method patents with exclusivity through 2043.

The business model is built on a capital-efficient, asset-light architecture in which Impact BioMedical retains ownership of its 69 issued and 60+ pending worldwide patents and monetizes them primarily through licensing, co-development, and royalty arrangements rather than internal clinical and commercial build-out. Strategic partners include ProPhase Labs (NASDAQ: PRPH) for Equivir and Linebacker development and commercialization, Chemia Corp for 3F manufacturing, and Dr. Ashleys Limited (Hong Kong) for a proposed reverse merger transaction targeted to close by July 1, 2026, intended to create a larger combined NYSE American-listed entity with global pharmaceutical manufacturing capabilities. Direct revenue is currently limited to consumer e-commerce sales of Celios products through dsspureair.com, which generated $32,000 in FY2025.

The company faces material financial headwinds including a $11.87M FY2025 net loss (improved from $24.77M in FY2024), a going concern audit qualification from Grassi & Co., CPAs, P.C. filed in the 2025 10-K, an underwriter securities class action investigation by Rosen Law Firm, and CEO/CFO share sale activity in 2026. Customer base is concentrated among a small set of strategic licensing and development partners and one consumer e-commerce channel, with no disclosed enterprise customers or contracted revenue.

Short descriptiontext

Impact BioMedical Inc. is a Houston-based, NYSE American-listed (IBO) biotechnology and consumer wellness company that develops patented polyphenol, botanical, and air purification platforms (Linebacker, Laetose, 3F, Equivir, Celios) and monetizes them through licensing partnerships with ProPhase Labs and Chemia Corp and direct-to-consumer e-commerce.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical research, consumer health products, polyphenol drug platforms, air purification technology, intellectual property licensing
Industry5 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYCRADABAM
Better-for-You / Functional Snacks (Low Sugar, Keto, Probiotic, Fortified)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals and Consumer Wellness
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing and Royalty Revenue
TypeLicensing Royalties
Description

Impact BioMedical licenses its proprietary technology platforms (Laetose, 3F, Linebacker, Equivir) to external partners. Laetose and 3F are described as 'proven and available for immediate partnering' with potential to generate both license milestone and royalty revenue in 2025 and beyond. ProPhase Labs is developing Equivir as an OTC health supplement, with potential milestone and royalty arrangements.

sec.gov
2Product Revenue — Celios Air Purification
TypeHardware Sales
Description

Revenue generated from the sale of Celios portable air purification products. Impact BioMedical acquired Celios in February 2025 in an all-equity transaction valued at approximately $1.15 million. First revenue from Celios ($32,000) was recorded in fiscal year 2025.

sec.gov
3Partnership Milestone Payments
TypeProfessional Services
Description

Co-development agreements with partners such as ProPhase Labs may generate upfront, development, regulatory, and commercial milestone payments. For example, Linebacker is under evaluation for oncology applications with pre-clinical studies ongoing, with results projected in 2025, advancing toward IND discussions and potential Phase 1 study initiation.

impactbiomedinc.com
4Merger and Strategic Transaction Value
TypeLicensing Royalties
Description

Impact BioMedical is pursuing a reverse merger with Dr. Ashleys Limited to create a new publicly traded entity on NYSE American, targeting completion by July 1, 2026. The transaction includes a $15 million debt conversion with DSS Inc. through issuance of 31.9 million shares, designed to strengthen the financial position of the combined entity.

sec.gov
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Impact BioMedical discovers, develops, patents, and commercializes proprietary biopharmaceutical and consumer wellness platforms through five core technologies: Linebacker (polyphenol oncology/anti-inflammatory pipeline), Laetose (low-glycemic sugar composition), Equivir (antiviral GRAS-eligible supplement), 3F (botanical insect repellent and antimicrobial), and Celios (portable air purification hardware). The company monetizes these primarily through licensing and co-development partnerships, with direct-to-consumer hardware sales via the Celios brand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Linebacker down-regulates PIM kinase which plays a key role as an oncogene in solid tumor cancers (lung and colon)
+4 more records
Product overview1 text field

Impact Biomedical is a pioneering biotechnology company that discovers, confirms, and patents unique science and technologies, transforming them into innovative human health and wellness solutions. The company operates a diversified portfolio organized across three segments: (1) Biopharmaceuticals including Linebacker™ for oncology, inflammatory disease, and neurology applications, and Laetose™ for metabolic/anti-inflammatory therapeutics; (2) Consumer Wellness including Equivir™ and Equivir-G™ (antiviral supplements), 3F™ (natural insect repellent and antimicrobial), and Laetose™ (dietary supplement); and (3) Air Purification through Celios®, acquired in February 2025 to expand the health and wellness portfolio. The company leverages strategic partnerships in licensing, co-development, and joint ventures to commercialize its proprietary technology platforms.

Product and service5 records
1Linebacker™
CategoryBiopharmaceutical Pipeline Platform
Description

A biopharmaceutical platform employing small molecule X-bonded polyphenols (Linebacker-1 and Linebacker-2) designed to improve potency, efficacy, bioavailability, and permeability of therapeutics. Down-regulates PIM kinase for solid tumor treatment. Targeted at oncology (lung, colon), inflammatory, and neurological disorders; being co-developed with ProPhase Labs toward IND discussions and potential Phase 1 studies.

2Laetose™
CategoryConsumer Wellness / Food Ingredient
Description

Low-glycemic sugar composition combining multiple sugars independently paired with myo-inositol to inhibit the inflammatory and metabolic response of sugar alone. Reduces caloric intake and glycemic index while inhibiting TNF-alpha. Applications span food and beverage, dietary supplements, and therapeutics for diabetes and inflammatory disease.

33F™ (Functional Fragrance Formulation)
CategoryConsumer Wellness / Botanical Ingredient
Description

Botanical formulation (e.g., terpenes) with demonstrated insect repellency and antimicrobial/antiviral effect. All-natural composition free of synthetic components, applicable to detergents, lotions, shampoos, fabrics, and antimicrobial coatings. Manufactured and developed in partnership with Chemia Corp.

4Equivir™ and Equivir-G™
CategoryConsumer Wellness / OTC Supplement
Description

Novel FDA GRAS-eligible polyphenol blend with proven antiviral effects, intended for OTC medication/supplement or Rx applications targeting upper respiratory infections. Equivir-G is a variant that adds gallic acid for an additional unique antiviral formulation. Developed in partnership with ProPhase Labs as an OTC health supplement.

5Celios® Air Purification Products
CategoryAir Purification Hardware
Description

Advanced portable air purification products delivering 'virtually clean room' air quality through patented US-manufactured filter technology. Design, system, and method patents issued in the US and other countries with exclusivity through 2043. Sold direct-to-consumer via the dsspureair.com e-commerce storefront.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-21
Description

Dr. Ashleys Limited, a Hong Kong-based global pharmaceutical company, and Impact BioMedical executed a merger and share exchange agreement on June 21, 2025, for a strategic reverse merger transaction. Upon closing, Dr. Ashleys will acquire Impact BioMedical through a reverse merger resulting in a newly formed combined entity (PubCo) traded on NYSE American under the name 'Dr Ashleys Limited.' The transaction aims to leverage Impact BioMedical's patent portfolio and expand global reach. Target closing: July 1, 2026.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-02-26
Description

Impact BioMedical acquired Celios, a pioneering air purification technology company, in an all-equity transaction valued at approximately $1.15 million. Celios brings advanced air purification capability with design, system, and method patents issued in the US and other countries with exclusivity through 2043.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ProPhase Labs is a global development and commercialization partner for Equivir and Linebacker technologies. Equivir is under development with initial application planned as an OTC health supplement, with studies ongoing to support market claims. Linebacker is under evaluation with initial oncology targets (lung, colon) with pre-clinical studies ongoing and results projected for 2025, advancing toward IND discussions and Phase 1 study plans.

4Chemia Corp
Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing Partner
Description

Chemia Corp, a global manufacturing and development partner based in St. Louis, MO, manufactures and develops 3F Functional Fragrance products. 3F is available for additional partnering and out-licensing. The partnership covers natural insect repellent and antimicrobial formulations.

impactbiomedinc.com
5Sichenzia Ross Ference Carmel LLP
Strategic tierSupportingTypeOthers
Description

Sichenzia Ross Ference Carmel LLP serves as US legal counsel to Impact BioMedical in connection with the proposed reverse merger with Dr. Ashleys Limited.

impactbiomedinc.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ProPhase Labs (NASDAQ: PRPH) is Impact BioMedical's primary development and commercialization partner for Equivir and Linebacker, and operates a comparable OTC supplement + diagnostics portfolio targeting consumer health channels. Its direct involvement in IBO's pipeline makes it the single most operationally comparable peer.

TypeDirect peer
Description

Aytu BioPharma (NASDAQ: AYTU) is a small-cap specialty pharma with a diversified prescription and consumer health product portfolio, similar in scale and microcap public-company profile to Impact BioMedical, with overlapping reliance on licensing and out-licensing for pipeline value capture.

3DSS Inc.
TypeBroad incumbent
Description

DSS Inc. (NYSE American: DSS) is Impact BioMedical's former parent and significant shareholder via the $15M debt conversion. DSS is a diversified conglomerate operating multiple subsidiaries in biotech, securities, and digital assets, providing the broader ecosystem context for IBO's spin-out and continuing capital relationship.

TypeDirect peer
Description

Tonix Pharmaceuticals (NASDAQ: TNXP) is a small-cap clinical-stage specialty pharma with multiple platform assets across CNS, immunology, and infectious disease—an analogous multi-platform microcap biotech structure to Impact BioMedical's Linebacker/Equivir strategy.

TypeDirect peer
Description

Citius Oncology (NASDAQ: CTOR) is a small specialty oncology pharmaceutical company targeting solid tumor and hematological cancers, directly comparable to Impact BioMedical's Linebacker oncology pipeline in scale, stage, and regulatory pathway.

TypeDirect peer
Description

BioXcel Therapeutics (NASDAQ: BTAI) is a clinical-stage biopharmaceutical company developing immunology and neuroscience therapies using AI-derived drug repurposing—a comparable microcap specialty pharma profile with multi-platform neurology/inflammation focus overlapping Linebacker's targets.

TypeEmerging player
Description

InMed Pharmaceuticals (NASDAQ: INM) is a small clinical-stage biotech developing plant-derived cannabinoid-like polyphenol therapies for neurological and dermatological conditions—comparable to Impact BioMedical's botanical polyphenol approach with Linebacker and Laetose, with similar early-stage commercialization risk.

TypeEmerging player
Description

Helius Medical Technologies is a small neurotech/medical device company where IBO COO Mark Suseck previously led global sales and marketing. It represents a peer-size and stage reference point for Impact BioMedical's pre-commercial specialty pharma/neurology positioning.

TypeDirect peer
Description

Salarius Pharmaceuticals (NASDAQ: SLRX) is a microcap clinical-stage oncology company with pipeline assets targeting epigenetic and protein-degradation mechanisms in solid tumors—comparable scale and development stage to Impact BioMedical's Linebacker oncology program.

TypeEmerging player
Description

Vivacitas Oncology is a small private oncology company where IBO COO Mark Suseck previously served as CEO. It is a relevant emerging-player reference for Impact BioMedical's pipeline structure and operational approach to early-stage oncology development and licensing.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Impact Biomedical

Biopharmaceuticals and Consumer Wellnessimpactbiomedinc.com

Impact BioMedical Inc. is a Houston-based, NYSE American-listed (IBO) biotechnology and consumer wellness company that develops patented polyphenol, botanical, and air purification platforms (Linebacker, Laetose, 3F, Equivir, Celios) and monetizes them through licensing partnerships with ProPhase Labs and Chemia Corp and direct-to-consumer e-commerce.

What Impact Biomedical does

Impact BioMedical Inc. is a publicly traded biotechnology and consumer wellness company (NYSE American: IBO), headquartered in Houston, Texas, that develops and patents science-based platforms targeting inflammatory disease, oncology, neurology, metabolic disorders, infectious disease, and indoor air quality. The company was spun out of DSS Inc. through an IPO in September 2024 and operates four core technology platforms: Linebacker (small-molecule X-bonded polyphenols designed to down-regulate PIM kinase for solid tumor cancers and inflammatory/neurological disorders), Laetose (a patented low-glycemic sugar composition with myo-inositol that inhibits TNF-alpha, covered by US Patent #11,898,184), Equivir (an FDA GRAS-eligible polyphenol blend with antiviral effects intended for OTC respiratory infection applications), and 3F (a botanical terpene-based formulation with insect repellent and antimicrobial properties). In February 2025 the company expanded into air purification via the acquisition of Celios, contributing its first reported revenue and adding design, system, and method patents with exclusivity through 2043.

The business model is built on a capital-efficient, asset-light architecture in which Impact BioMedical retains ownership of its 69 issued and 60+ pending worldwide patents and monetizes them primarily through licensing, co-development, and royalty arrangements rather than internal clinical and commercial build-out. Strategic partners include ProPhase Labs (NASDAQ: PRPH) for Equivir and Linebacker development and commercialization, Chemia Corp for 3F manufacturing, and Dr. Ashleys Limited (Hong Kong) for a proposed reverse merger transaction targeted to close by July 1, 2026, intended to create a larger combined NYSE American-listed entity with global pharmaceutical manufacturing capabilities. Direct revenue is currently limited to consumer e-commerce sales of Celios products through dsspureair.com, which generated $32,000 in FY2025.

The company faces material financial headwinds including a $11.87M FY2025 net loss (improved from $24.77M in FY2024), a going concern audit qualification from Grassi & Co., CPAs, P.C. filed in the 2025 10-K, an underwriter securities class action investigation by Rosen Law Firm, and CEO/CFO share sale activity in 2026. Customer base is concentrated among a small set of strategic licensing and development partners and one consumer e-commerce channel, with no disclosed enterprise customers or contracted revenue.

Impact Biomedical firmographics

Firmographics
Name
Impact Biomedical
Legal name
Impact BioMedical Inc.
Website
https://impactbiomedinc.com
Company type
Public
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Impact BioMedical Inc. is a Houston-based, NYSE American-listed (IBO) biotechnology and consumer wellness company that develops patented polyphenol, botanical, and air purification platforms (Linebacker, Laetose, 3F, Equivir, Celios) and monetizes them through licensing partnerships with ProPhase Labs and Chemia Corp and direct-to-consumer e-commerce.
Ownership category
akta.pro rank

Impact Biomedical industry classification

Industry
Product category
Biopharmaceuticals and Consumer Wellness
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYCRADABAM
Better-for-You / Functional Snacks (Low Sugar, Keto, Probiotic, Fortified)

Keywords

  • Biopharmaceutical research
  • Consumer health products
  • Polyphenol drug platforms
  • Air purification technology
  • Intellectual property licensing

Where Impact Biomedical is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Impact Biomedical business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Licensing and Royalty Revenue: Impact BioMedical licenses its proprietary technology platforms (Laetose, 3F, Linebacker, Equivir) to external partners. Laetose and 3F are described as 'proven and available for immediate partnering' with potential to generate both license milestone and royalty revenue in 2025 and beyond. ProPhase Labs is developing Equivir as an OTC health supplement, with potential milestone and royalty arrangements.
  2. Product Revenue — Celios Air Purification: Revenue generated from the sale of Celios portable air purification products. Impact BioMedical acquired Celios in February 2025 in an all-equity transaction valued at approximately $1.15 million. First revenue from Celios ($32,000) was recorded in fiscal year 2025.
  3. Partnership Milestone Payments: Co-development agreements with partners such as ProPhase Labs may generate upfront, development, regulatory, and commercial milestone payments. For example, Linebacker is under evaluation for oncology applications with pre-clinical studies ongoing, with results projected in 2025, advancing toward IND discussions and potential Phase 1 study initiation.
  4. Merger and Strategic Transaction Value: Impact BioMedical is pursuing a reverse merger with Dr. Ashleys Limited to create a new publicly traded entity on NYSE American, targeting completion by July 1, 2026. The transaction includes a $15 million debt conversion with DSS Inc. through issuance of 31.9 million shares, designed to strengthen the financial position of the combined entity.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Impact Biomedical product offering

Product offering

Core offering

Impact BioMedical discovers, develops, patents, and commercializes proprietary biopharmaceutical and consumer wellness platforms through five core technologies: Linebacker (polyphenol oncology/anti-inflammatory pipeline), Laetose (low-glycemic sugar composition), Equivir (antiviral GRAS-eligible supplement), 3F (botanical insect repellent and antimicrobial), and Celios (portable air purification hardware). The company monetizes these primarily through licensing and co-development partnerships, with direct-to-consumer hardware sales via the Celios brand.

Product overview

Impact Biomedical is a pioneering biotechnology company that discovers, confirms, and patents unique science and technologies, transforming them into innovative human health and wellness solutions. The company operates a diversified portfolio organized across three segments: (1) Biopharmaceuticals including Linebacker™ for oncology, inflammatory disease, and neurology applications, and Laetose™ for metabolic/anti-inflammatory therapeutics; (2) Consumer Wellness including Equivir™ and Equivir-G™ (antiviral supplements), 3F™ (natural insect repellent and antimicrobial), and Laetose™ (dietary supplement); and (3) Air Purification through Celios®, acquired in February 2025 to expand the health and wellness portfolio. The company leverages strategic partnerships in licensing, co-development, and joint ventures to commercialize its proprietary technology platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Linebacker™ A biopharmaceutical platform employing small molecule X-bonded polyphenols (Linebacker-1 and Linebacker-2) designed to improve potency, efficacy, bioavailability, and permeability of therapeutics. Down-regulates PIM kinase for solid tumor treatment. Targeted at oncology (lung, colon), inflammatory, and neurological disorders; being co-developed with ProPhase Labs toward IND discussions and potential Phase 1 studies.
  • Laetose™ Low-glycemic sugar composition combining multiple sugars independently paired with myo-inositol to inhibit the inflammatory and metabolic response of sugar alone. Reduces caloric intake and glycemic index while inhibiting TNF-alpha. Applications span food and beverage, dietary supplements, and therapeutics for diabetes and inflammatory disease.
  • 3F™ (Functional Fragrance Formulation) Botanical formulation (e.g., terpenes) with demonstrated insect repellency and antimicrobial/antiviral effect. All-natural composition free of synthetic components, applicable to detergents, lotions, shampoos, fabrics, and antimicrobial coatings. Manufactured and developed in partnership with Chemia Corp.
  • Equivir™ and Equivir-G™ Novel FDA GRAS-eligible polyphenol blend with proven antiviral effects, intended for OTC medication/supplement or Rx applications targeting upper respiratory infections. Equivir-G is a variant that adds gallic acid for an additional unique antiviral formulation. Developed in partnership with ProPhase Labs as an OTC health supplement.
  • Celios® Air Purification Products Advanced portable air purification products delivering 'virtually clean room' air quality through patented US-manufactured filter technology. Design, system, and method patents issued in the US and other countries with exclusivity through 2043. Sold direct-to-consumer via the dsspureair.com e-commerce storefront.

Quantifiable outcome

  • Linebacker down-regulates PIM kinase which plays a key role as an oncogene in solid tumor cancers (lung and colon)
  • +4 more outcomes

Companies that use Impact Biomedical

Customer profile

Segments3 records

Ideal customer profiles3 records

Impact Biomedical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Impact Biomedical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and supporting.

  • Dr. Ashleys LimitedcoreStrategic or Co-development Partner · 21 June 2025Dr. Ashleys Limited, a Hong Kong-based global pharmaceutical company, and Impact BioMedical executed a merger and share exchange agreement on June 21, 2025, for a strategic reverse merger transaction. Upon closing, Dr. Ashleys will acquire Impact BioMedical through a reverse merger resulting in a newly formed combined entity (PubCo) traded on NYSE American under the name 'Dr Ashleys Limited.' The transaction aims to leverage Impact BioMedical's patent portfolio and expand global reach. Target closing: July 1, 2026.
  • Celios®supportingStrategic or Co-development Partner · 26 February 2025Impact BioMedical acquired Celios, a pioneering air purification technology company, in an all-equity transaction valued at approximately $1.15 million. Celios brings advanced air purification capability with design, system, and method patents issued in the US and other countries with exclusivity through 2043.
  • ProPhase Labs (NASDAQ: PRPH)coreStrategic or Co-development PartnerProPhase Labs is a global development and commercialization partner for Equivir and Linebacker technologies. Equivir is under development with initial application planned as an OTC health supplement, with studies ongoing to support market claims. Linebacker is under evaluation with initial oncology targets (lung, colon) with pre-clinical studies ongoing and results projected for 2025, advancing toward IND discussions and Phase 1 study plans.
  • Chemia CorpsupportingOEM/ Whitelabel/ Licensing PartnerChemia Corp, a global manufacturing and development partner based in St. Louis, MO, manufactures and develops 3F Functional Fragrance products. 3F is available for additional partnering and out-licensing. The partnership covers natural insect repellent and antimicrobial formulations.
  • Sichenzia Ross Ference Carmel LLPsupportingOthersSichenzia Ross Ference Carmel LLP serves as US legal counsel to Impact BioMedical in connection with the proposed reverse merger with Dr. Ashleys Limited.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Impact Biomedical competitors and assessment

Company assessment

Direct peers

  • ProPhase Labs: ProPhase Labs (NASDAQ: PRPH) is Impact BioMedical's primary development and commercialization partner for Equivir and Linebacker, and operates a comparable OTC supplement + diagnostics portfolio targeting consumer health channels. Its direct involvement in IBO's pipeline makes it the single most operationally comparable peer.
  • Aytu BioPharma: Aytu BioPharma (NASDAQ: AYTU) is a small-cap specialty pharma with a diversified prescription and consumer health product portfolio, similar in scale and microcap public-company profile to Impact BioMedical, with overlapping reliance on licensing and out-licensing for pipeline value capture.
  • Tonix Pharmaceuticals: Tonix Pharmaceuticals (NASDAQ: TNXP) is a small-cap clinical-stage specialty pharma with multiple platform assets across CNS, immunology, and infectious disease—an analogous multi-platform microcap biotech structure to Impact BioMedical's Linebacker/Equivir strategy.
  • Citius Oncology: Citius Oncology (NASDAQ: CTOR) is a small specialty oncology pharmaceutical company targeting solid tumor and hematological cancers, directly comparable to Impact BioMedical's Linebacker oncology pipeline in scale, stage, and regulatory pathway.
  • BioXcel Therapeutics: BioXcel Therapeutics (NASDAQ: BTAI) is a clinical-stage biopharmaceutical company developing immunology and neuroscience therapies using AI-derived drug repurposing—a comparable microcap specialty pharma profile with multi-platform neurology/inflammation focus overlapping Linebacker's targets.
  • Salarius Pharmaceuticals: Salarius Pharmaceuticals (NASDAQ: SLRX) is a microcap clinical-stage oncology company with pipeline assets targeting epigenetic and protein-degradation mechanisms in solid tumors—comparable scale and development stage to Impact BioMedical's Linebacker oncology program.

Broad incumbents

  • DSS Inc. DSS Inc. (NYSE American: DSS) is Impact BioMedical's former parent and significant shareholder via the $15M debt conversion. DSS is a diversified conglomerate operating multiple subsidiaries in biotech, securities, and digital assets, providing the broader ecosystem context for IBO's spin-out and continuing capital relationship.

Emerging players

  • InMed Pharmaceuticals: InMed Pharmaceuticals (NASDAQ: INM) is a small clinical-stage biotech developing plant-derived cannabinoid-like polyphenol therapies for neurological and dermatological conditions—comparable to Impact BioMedical's botanical polyphenol approach with Linebacker and Laetose, with similar early-stage commercialization risk.
  • Helius Medical Technologies: Helius Medical Technologies is a small neurotech/medical device company where IBO COO Mark Suseck previously led global sales and marketing. It represents a peer-size and stage reference point for Impact BioMedical's pre-commercial specialty pharma/neurology positioning.
  • Vivacitas Oncology: Vivacitas Oncology is a small private oncology company where IBO COO Mark Suseck previously served as CEO. It is a relevant emerging-player reference for Impact BioMedical's pipeline structure and operational approach to early-stage oncology development and licensing.

Market position

Strengths2 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Impact Biomedical social profiles

Digital presence

Impact Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Impact Biomedical leadership team

Management profile

Number of profiles

Profiles3 records

Impact Biomedical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Impact Biomedical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Impact Biomedical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impact Biomedical

What does Impact Biomedical do?

Impact BioMedical discovers, develops, patents, and commercializes proprietary biopharmaceutical and consumer wellness platforms through five core technologies: Linebacker (polyphenol oncology/anti-inflammatory pipeline), Laetose (low-glycemic sugar composition), Equivir (antiviral GRAS-eligible supplement), 3F (botanical insect repellent and antimicrobial), and Celios (portable air purification hardware). The company monetizes these primarily through licensing and co-development partnerships, with direct-to-consumer hardware sales via the Celios brand.

Is Impact Biomedical a public or private company?

Impact Biomedical is a public company. It is classified as public and is currently operating.

When was Impact Biomedical founded?

Impact Biomedical was founded in 2024. It employs 1 to 10 people.

Where is Impact Biomedical based?

Impact Biomedical is headquartered in Houston, United States, in the North America region.

How does Impact Biomedical make money?

Four revenue lines are on record. Licensing and Royalty Revenue is the primary driver. The others are product Revenue — Celios Air Purification, partnership Milestone Payments and merger and Strategic Transaction Value.

Who are Impact Biomedical's main competitors?

Direct peers on record are ProPhase Labs, Aytu BioPharma, Tonix Pharmaceuticals, Citius Oncology, BioXcel Therapeutics and Salarius Pharmaceuticals. DSS Inc. is listed as a broad incumbent. Emerging players are InMed Pharmaceuticals, Helius Medical Technologies and Vivacitas Oncology.

Does Impact Biomedical have an API?

No public API is recorded for Impact Biomedical.

What industry is Impact Biomedical in?

Impact Biomedical's product category is Biopharmaceuticals and Consumer Wellness. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coZoar lists on NYSE American via Impact Biomedical merger backed by DSS | Dealroom NewsImpact Biomedical completed its merger with Zoar Limited and Zoar Labs, listing Zoar USA Inc. on the NYSE American under ticker ZOAR on November 18, 2026. Zoar Labs reported $651.7 million revenue and $77.7 million net income for fiscal 2026, up 17.1% and 23.9% year over year. The deal gives Zoar a public listing but leaves DSS's ownership and proceeds undisclosed.Stock TitanDSS Completes Impact Biomedical Deal With ZoarDSS's Impact Biomedical completed its business combination with Zoar Limited and Zoar Labs, becoming a wholly owned Zoar subsidiary renamed Zoar USA Inc. Zoar shares begin trading on the NYSE American under "ZOAR" on November 18, 2026. Zoar Labs reported $651.7 million revenue and $77.7 million net income for fiscal 2026.FinancialContent Business PageZoar Limited Completes Business Combination with Impact Biomedical Inc.Zoar Limited completed its business combination with Impact Biomedical, with shares expected to trade on NYSE American under "ZOAR" on November 18, 2026. Zoar Labs reported revenue of $651.7 million and net income of $77.7 million for the fiscal year ended March 31, 2026. The company plans to expand its product offering in orphan drug APIs.Stock TitanZoar Completes Impact Biomedical Business CombinationZoar Limited completed its business combination with Impact Biomedical, with shares trading on NYSE American under 'ZOAR' on November 18, 2026. Zoar Labs reported revenue of $651.7 million and net income of $77.7 million for fiscal 2026. The company plans to expand its product offering in orphan drug APIs.FinanzNachrichten.deImpact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed BusineImpact Biomedical and Zoar Limited announced the SEC declared the Form F-4 registration statement effective on October 23, 2026, marking a milestone toward their business combination. The combined company will trade as Zoar Limited on NYSE American under the ticker 'ZOAR,' with a stockholder vote scheduled for November 13, 2026.TradingViewDSS, Inc. (DSS) Form F-4 Effective; Impact Vote Set for Nov. 13The SEC declared Zoar Limited's Form F-4 effective on October 23, 2026, for the proposed business combination with Impact Biomedical and Zoar Labs. Impact stockholders will vote on the transaction on November 13, with closing subject to approvals and other conditions.Stock TitanDSS: SEC Makes PubCo's Form F-4 Effective for Proposed DealDSS, Inc. announced the SEC declared PubCo's Form F-4 effective on October 23, 2026, for the proposed business combination with Impact Biomedical and Zoar Labs. The combination is expected to create a pharmaceutical company developing active ingredients and intermediates. Impact's stockholder vote is scheduled for November 13, 2026.The future of tradingImpact Biomedical Announces Special Stockholder MeetingImpact Biomedical will hold a special stockholder meeting on November 13, 2026, to vote on the Merger and Share Exchange Agreement governing its proposed business combination with Zoar Limited and Zoar Labs. The meeting is scheduled for that date, with voting on the agreement.TradingViewImpact Biomedical Inc. (IBO) Form F-4 Effective; Shareholder Vote Set for Nov. 13The SEC declared Zoar Limited's Form F-4 effective on October 23 for its proposed business combination with Impact Biomedical and Zoar Labs. Impact's stockholder vote is set for November 13, 2026, with closing subject to approval and other conditions.TradingViewImpact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business CombinationImpact Biomedical and Zoar Limited announced the SEC declared the Form F-4 registration statement effective on October 23, 2026, for their proposed business combination. A special stockholder meeting is scheduled for November 13, 2026, to vote on the merger, with the combined company expected to trade as ZOAR on NYSE American.